このエントリーをはてなブックマークに追加
ID 34996
本文ファイル
著者
Ishihara, Aiko
Miyachi, Takafumi
Nakamura, Takeshi
Ohtsuki, Toshiho
Yamawaki, Takemori
キーワード
Parkinson's disease
3-OMD
Entacapone
Levodopa AUC
NDC
医学
抄録(英)
The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMTindex was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.
掲載誌名
Hiroshima Journal of Medical Sciences
60巻
3号
開始ページ
57
終了ページ
62
出版年月日
2011-09
出版者
Hiroshima University Medical Press
ISSN
0018-2052
NCID
言語
英語
NII資源タイプ
紀要論文
広大資料タイプ
学内刊行物(紀要等)
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
権利情報
(c) Hiroshima University Medical Press.
部局名
医歯薬学総合研究科
病院
他の一覧



過去1年のアクセス数 : ?
過去1年の本文閲覧数 : ?


今月のアクセス数 : ?
今月の本文閲覧数 : ?